Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2018-99-110543

Published: 2018

Journal Articles

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Michael W. Deininger, MD PhD, Vamsi Kota, MBBS, Jeff H. Lipton, MD PhD, Dragana Milojkovic, MBBS, PhD, Valentín García Gutiérrez, PhD, Eric Leip, PhD, Sonja Nick, MSc, Andreas Hochhaus, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Tim H. Brummendorf, MD

Blood (2018) 132 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2018-99-110798

Published: 2018

Journal Articles

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Rocco J. Crescenzo, MD, Eric Leip, PhD, Andrea Viqueira, MD, Bart Heeg, PhD

Blood (2018) 132 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2018-99-114827

Published: 2018

Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 896.

https://doi.org/10.1182/blood.V130.Suppl_1.896.896

Published: 2017

Journal Articles

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, MD PhD, Yeow Tee Goh, MBBS,MD, Iryna Dyagil, MDPhD, Katia B Pagnano, MD, Árpád Bátai, MD, Anna G Turkina, Prof., MD, Jean M. Aguiar, RN, Eric Leip, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 900.

https://doi.org/10.1182/blood.V130.Suppl_1.900.900

Published: 2017

Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Andreas Hochhaus, Prof. Dr., Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Nataliia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Laurence Reilly, Allison Jeynes-Ellis, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Timothy H. Brümmendorf, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1618.

https://doi.org/10.1182/blood.V130.Suppl_1.1618.1618

Published: 2017

Journal Articles

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Blood (2017) 130 (Supplement 1): 1620.

https://doi.org/10.1182/blood.V130.Suppl_1.1620.1620

Published: 2017

Journal Articles

Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy

Jorge E. Cortes, MD, Dong-Wook Kim, MD PhD, Hagop M. Kantarjian, MD, Michael J. Mauro, MD, Jean M. Aguiar, RN, Fiona An, MD, Eric Leip, PhD, Carlo Gambacorti-Passerini, MD, Tim H. Brummendorf, MD

Blood (2017) 130 (Supplement 1): 1590.

https://doi.org/10.1182/blood.V130.Suppl_1.1590.1590

Published: 2017

Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP

Blood (2016) 128 (22): 1921.

https://doi.org/10.1182/blood.V128.22.1921.1921

Published: 2016

Journal Articles

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Jorge E. Cortes, Tim H. Brümmendorf, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Sashi Nadanaciva, D Phil, Nathalie Bardy-Bouxin, PhD, Mark Shapiro, MD, Eric Leip, PhD, Jeffrey H. Lipton, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2015) 126 (23): 4041.

https://doi.org/10.1182/blood.V126.23.4041.4041

Published: 2015

Journal Articles

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

Carlo Gambacorti-Passerini, MD, H. Jean Khoury, Hagop M. Kantarjian, MD, Jeffrey H. Lipton, MD PhD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Ewa M. Matczak, MD, Eric Leip, PhD, Kay Noonan, Tim H. Brümmendorf, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 4559.

https://doi.org/10.1182/blood.V124.21.4559.4559

Published: 2014

Journal Articles

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Mirjana Zeremski, MD, Mark Shapiro, MD, Eric Leip, PhD, Carlo Gambacorti-Passerini, MD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 5544.

https://doi.org/10.1182/blood.V124.21.5544.5544

Published: 2014

Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD

Blood (2013) 122 (21): 1484.

https://doi.org/10.1182/blood.V122.21.1484.1484

Published: 2013

Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Carlo Gambacorti-Passerini, MD, Jeff H. Lipton, PhD, MD

Blood (2013) 122 (21): 2723.

https://doi.org/10.1182/blood.V122.21.2723.2723

Published: 2013

Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Jeff H. Lipton, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD

Blood (2013) 122 (21): 4025.

https://doi.org/10.1182/blood.V122.21.4025.4025

Published: 2013

NARROW

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial

Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only